IN2014CH00391A - - Google Patents
Info
- Publication number
- IN2014CH00391A IN2014CH00391A IN391CH2014A IN2014CH00391A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A IN 391CH2014 A IN391CH2014 A IN 391CH2014A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A
- Authority
- IN
- India
- Prior art keywords
- cellular immunity
- peptide
- cancer
- composition
- subject
- Prior art date
Links
- 230000007969 cellular immunity Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013020906 | 2013-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CH00391A true IN2014CH00391A (no) | 2015-04-03 |
Family
ID=50028737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN391CH2014 IN2014CH00391A (no) | 2013-02-05 | 2014-01-29 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10449144B2 (no) |
| EP (1) | EP2762159A1 (no) |
| JP (1) | JP6512568B2 (no) |
| KR (1) | KR20140100419A (no) |
| CN (1) | CN103961307B (no) |
| CA (1) | CA2841016A1 (no) |
| IN (1) | IN2014CH00391A (no) |
| RU (1) | RU2687144C2 (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| US20150150975A1 (en) * | 2012-07-02 | 2015-06-04 | Sumitomo Dainippon Pharma Co., Ltd. | Transdermal cancer antigen peptide preparation |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| DK2945647T3 (da) | 2013-01-15 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Immunogene wt-1-peptider og anvendelsesmetoder deraf |
| JP6512569B2 (ja) * | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤 |
| IN2014CH00391A (no) | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
| KR20150126042A (ko) | 2013-03-12 | 2015-11-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 액체 수성 조성물 |
| CN106687138B (zh) * | 2014-09-03 | 2021-10-15 | 日东电工株式会社 | 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物 |
| WO2016052698A1 (ja) * | 2014-10-02 | 2016-04-07 | 日東電工株式会社 | 経皮投与用ワクチン医薬組成物 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| PT1103564E (pt) | 1998-07-31 | 2009-03-13 | Int Inst Cancer Immunology Inc | Antigénios de cancro com base no produto do gene supressor de tumor wt1 |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| US20030082194A1 (en) * | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| RU2192884C2 (ru) | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| ES2298353T3 (es) | 2001-03-22 | 2008-05-16 | International Institute Of Cancer Immunology, Inc. | Peptido wt1 modificado. |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| EP1536009B1 (en) * | 2002-06-12 | 2010-04-28 | International Institute of Cancer Immunology, Inc. | Hla-a24-restricted cancer antigen peptide |
| US7378384B2 (en) | 2002-09-20 | 2008-05-27 | International Institute Of Cancer Immunology, Inc. | WT1 substitution peptides |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| EP2071028B1 (en) | 2003-11-05 | 2012-01-04 | International Institute of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| EP2186896B1 (en) | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
| DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| RU2424247C2 (ru) | 2005-11-30 | 2011-07-20 | Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. | Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка |
| GB2448255A (en) * | 2005-12-01 | 2008-10-08 | Trinity College Dublin | Compositions and methods relating to treatment of cancer and infectious diseases |
| JP5393144B2 (ja) | 2006-02-22 | 2014-01-22 | 株式会社癌免疫研究所 | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 |
| US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
| JP4925039B2 (ja) | 2006-09-21 | 2012-04-25 | 日東電工株式会社 | 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤 |
| US7935350B2 (en) * | 2006-12-14 | 2011-05-03 | Antigen Express, Inc. | Ii-key/Her-2/neu hybrid cancer vaccine |
| NZ601175A (en) | 2006-12-28 | 2012-12-21 | Int Inst Cancer Immunology Inc | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| WO2008093772A1 (ja) * | 2007-01-31 | 2008-08-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| RU2682726C9 (ru) | 2007-12-05 | 2019-08-15 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Вакцинная композиция против злокачественной опухоли |
| DK2119726T5 (en) * | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
| AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| AU2010307075B2 (en) | 2009-10-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Granulysin in immunotherapy |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| IN2014CH00391A (no) | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
| CA2840954A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
| CN103961701B (zh) * | 2013-02-05 | 2018-09-14 | 日东电工株式会社 | 疫苗组合物 |
| IN2014CH00390A (no) * | 2013-02-05 | 2015-07-31 | Nitto Denko Corp | |
| JP6512569B2 (ja) * | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤 |
-
2014
- 2014-01-29 IN IN391CH2014 patent/IN2014CH00391A/en unknown
- 2014-01-29 JP JP2014014802A patent/JP6512568B2/ja not_active Expired - Fee Related
- 2014-01-29 CN CN201410043149.8A patent/CN103961307B/zh not_active Expired - Fee Related
- 2014-01-29 EP EP14000324.5A patent/EP2762159A1/en not_active Withdrawn
- 2014-01-29 US US14/166,932 patent/US10449144B2/en active Active
- 2014-01-29 RU RU2014102936A patent/RU2687144C2/ru not_active IP Right Cessation
- 2014-01-29 CA CA2841016A patent/CA2841016A1/en not_active Abandoned
- 2014-01-29 KR KR1020140011634A patent/KR20140100419A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6512568B2 (ja) | 2019-05-15 |
| US20140220055A1 (en) | 2014-08-07 |
| RU2014102936A (ru) | 2015-08-10 |
| US10449144B2 (en) | 2019-10-22 |
| CN103961307B (zh) | 2019-11-29 |
| KR20140100419A (ko) | 2014-08-14 |
| JP2014169277A (ja) | 2014-09-18 |
| CA2841016A1 (en) | 2014-08-05 |
| CN103961307A (zh) | 2014-08-06 |
| RU2687144C2 (ru) | 2019-05-07 |
| EP2762159A1 (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CH00391A (no) | ||
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
| CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| IN2014CH00393A (no) | ||
| MD4733C1 (ro) | Anticorpi anti-TIGIT | |
| IN2014CH00396A (no) | ||
| MX2015010880A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| IN2014CH00395A (no) | ||
| MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
| SG10201903119QA (en) | Polypeptide vaccine | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| MX2016002937A (es) | Vacuna oncologica. | |
| SG10201808746QA (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
| MY191539A (en) | Streptococcal vaccine | |
| MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| NZ764154A (en) | New cath2 derivatives |